We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Moderna (MRNA) Falls More Steeply Than Broader Market: What Investors Need to Know
Read MoreHide Full Article
In the latest trading session, Moderna (MRNA - Free Report) closed at $30.41, marking a -2.38% move from the previous day. This move lagged the S&P 500's daily loss of 0.14%. On the other hand, the Dow registered a loss of 0.2%, and the technology-centric Nasdaq decreased by 0.24%.
Shares of the biotechnology company witnessed a gain of 28.93% over the previous month, beating the performance of the Medical sector with its loss of 0.56%, and the S&P 500's gain of 0.94%.
The investment community will be paying close attention to the earnings performance of Moderna in its upcoming release. It is anticipated that the company will report an EPS of -$2.79, marking a 11.6% fall compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $683.27 million, reflecting a 29.27% fall from the equivalent quarter last year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$7.93 per share and revenue of $1.95 billion. These totals would mark changes of +10.6% and -39.76%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for Moderna. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 2.02% upward. Moderna is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 106, positioning it in the top 43% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Moderna (MRNA) Falls More Steeply Than Broader Market: What Investors Need to Know
In the latest trading session, Moderna (MRNA - Free Report) closed at $30.41, marking a -2.38% move from the previous day. This move lagged the S&P 500's daily loss of 0.14%. On the other hand, the Dow registered a loss of 0.2%, and the technology-centric Nasdaq decreased by 0.24%.
Shares of the biotechnology company witnessed a gain of 28.93% over the previous month, beating the performance of the Medical sector with its loss of 0.56%, and the S&P 500's gain of 0.94%.
The investment community will be paying close attention to the earnings performance of Moderna in its upcoming release. It is anticipated that the company will report an EPS of -$2.79, marking a 11.6% fall compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $683.27 million, reflecting a 29.27% fall from the equivalent quarter last year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$7.93 per share and revenue of $1.95 billion. These totals would mark changes of +10.6% and -39.76%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for Moderna. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 2.02% upward. Moderna is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 106, positioning it in the top 43% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.